We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
England’s National Health Service has lifted restrictions on Janssen’s blood cancer drug Imbruvica (ibrutinib), after a journalist who was suffering from chronic lymphocytic leukaemia (CLL) was denied access.